Previous 10 | Next 10 |
Headed into a three-day holiday weekend, stocks lost ground on Thursday, reversing an attempted recovery posted in the previous session. Tech stocks led the retreat, contributing to a 2.1% slide in the Nasdaq. Drug development news provided a significant catalyst during the session. Valneva (...
Gainers: MedAvail Holdings (MDVL) +51%. Borqs Technologies (BRQS) +27%. Verastem (VSTM) +26%. Lexaria Bioscience (LEXX) +22%. Splash Beverage Group (SBEV) +18%. HighPeak Energy (HPK) +17%. Cardiol Therapeutics (CRDL) +16%. Airgain (AIRG) +15%. CoreCivic (CXW) +14%. Renren (RENN) +13%. Losers:...
Shares of Protagonist Therapeutics (NASDAQ:PTGX) have tumbled 22% on Thursday after the company disclosed in an securities filing after the closing bell Wednesday that the U.S. FDA intends to remove Breakthrough Therapy designation for rusfertide for polycythemia vera. The agency in...
Gainers: Lexaria Bioscience (LEXX) +23%. Rite Aid (RAD) +14%. Inozyme Pharma (INZY) +12%. Finch Therapeutics (FNCH) +11%. Valneva (VALN) +9%. Losers: Protagonist Therapeutics (PTGX) -23%. Lixte Biotechnology (LIXT) -10%. Biofrontera (BFRI) ...
Gainers: Eargo (EAR) +13%. Intel Corporation (INTC) +6%. eHealth (EHTH) +4%. Trevi Therapeutics (TRVI) +3%. Pacific Biosciences of California (PACB) +3%. Losers: Protagonist Therapeutics (PTGX) -34%. Cambium Networks Corporation (CMBM) -12%. Vir Biotechnology (VIR) -...
Protagonist Therapeutics (NASDAQ:PTGX) appoints Asif Ali as CFO and Executive VP. Asif will join the company in mid-April. Most recently he served as Chief Accounting Officer at Theravance Biopharma. For further details see: Asif Ali is the new finance chief at Protagonist The...
Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer PR Newswire NEWARK, Calif. , March 28, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) today announced the appointment of A...
Gainers: BiondVax Pharmaceuticals (BVXV) +39%. Alpha Tau Medical (DRTS) +38%. CollPlant Biotechnologies (CLGN) +10%. Aptevo Therapeutics (APVO) +8%. HOOKIPA Pharma (HOOK) +8%. Losers: Sonendo (SONX) -11%. Creative Medical Technology (CELZ) -9%. Lan...
Protagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for Dosing of Third Patient in Phase 2b Clinical Trial of PN-235 in Moderate-to-Severe Plaque Psoriasis PR Newswire Phase 2b clinical trial of PN-235, an oral IL-23 receptor antagonis...
Gainers: CTI BioPharma (NASDAQ:CTIC) +40%. Oak Street Health (NYSE:OSH) +23%. AVITA Medical (NASDAQ:RCEL) +15%. Axsome Therapeutics (NASDAQ:AXSM) +14%. Protagonist Therapeutics (NASDAQ:PTGX) +12%. Losers: GoodRx Holdings (NASDAQ:GDRX) -40%. Semler Scientific...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...